Product Center
HRK-X®'s first landing in Macau
- Categories:Company news
- Author:
- Origin:
- Time of issue:2025-12-05
- Views:
(Summary description)Recently, the company's independently developed quadrivalent influenza virus subunit vaccine, HRK-X®, has successfully arrived in the Macau Special Administrative Region and completed customs clearance, achieving the first batch of supply and officially entering the Macau market, successfully completing the company's first overseas market access and landing. This is not only an important symbol of the company's scientific research strength and production quality being widely recognized, but also an important step in the company's exploration of global commercialization.
HRK-X®'s first landing in Macau
(Summary description)Recently, the company's independently developed quadrivalent influenza virus subunit vaccine, HRK-X®, has successfully arrived in the Macau Special Administrative Region and completed customs clearance, achieving the first batch of supply and officially entering the Macau market, successfully completing the company's first overseas market access and landing. This is not only an important symbol of the company's scientific research strength and production quality being widely recognized, but also an important step in the company's exploration of global commercialization.
- Categories:Company news
- Author:
- Origin:
- Time of issue:2025-12-05 09:03
- Views:
Recently, the company's independently developed quadrivalent influenza virus subunit vaccine, HRK-X®, has successfully arrived in the Macau Special Administrative Region and completed customs clearance, achieving the first batch of supply and officially entering the Macau market, successfully completing the company's first overseas market access and landing. This is not only an important symbol of the company's scientific research strength and production quality being widely recognized, but also an important step in the company's exploration of global commercialization.
The quadrivalent influenza virus subunit vaccine (HRK-X®) supplied to Macau this time adopts advanced third-generation influenza vaccine technology, which includes the main surface antigens of two types of influenza A and two types of influenza B viruses. It has the characteristics of high purity, good safety, and strong immunogenicity. Compared with traditional vaccines, this product further optimizes the process, significantly improves the safety and protective effect of vaccination, and is suitable for vaccination for various groups including high-risk populations.
On December 4th, the first dose of the vaccine was successfully administered at the Yin Kui Hospital in Macau. The event conveyed the concept of "active health and proactive prevention" to various sectors in Macau, and vividly demonstrated our company's corporate vision of "enabling China to use globally innovative vaccines and the world to use high-quality Chinese vaccines".
The business leader of the company stated in his speech, "We are very honored to bring this advanced subunit influenza vaccine to our compatriots in Macau. This cooperation is not only a breakthrough in market expansion, but also an important step for us to fulfill our corporate vision. We will continue to support Macau's public health cause and work together to safeguard the health of Macau residents.
Relevant information
-
Deepening Strategic Synergy to Jointly Strengthen Public Health Defense: Chongqing Center for Disease Control and Prevention (Chongqing Institute of Preventive Medicine) visited Ab&B Bio for a visit and exchange session.On August 5, 2026, a delegation comprising leaders and experts from the Chongqing Center for Disease Control and Prevention (Chongqing Institute of Preventive Medicine) visited Ab&B Bio-Tech CO.,LTD.JS to conduct an on-site inspection and hold a symposium. During the meeting, both parties engaged in in-depth discussions on topics such as innovative vaccine R&D, clinical evaluation, joint construction of technical platforms, sharing of data resources, talent cultivation, and technology commercialization, thereby accelerating the transition of their strategic cooperation from "paper-based consensus" to "substantive implementation." - The world's first! The monkeypox mRNA vaccine has obtained dual clinical trial approvals from both China and the United States. 07-02
- Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially Launched 05-13
- The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating. 05-08
- Our innovative vaccine research team won the 20th "Jiangsu Youth May Fourth Medal Collective" award 04-27
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
